Rabeprazole
Rabeprazole. Proton pump inhibitor — H+/K+-ATPase irreversible inhibitor. Less CYP2C19-dependent metabolism than omeprazole; relative DDI… Oral half-life 1 h.
Proton pump inhibitor — H+/K+-ATPase irreversible inhibitor. Less CYP2C19-dependent metabolism than omeprazole; relative DDI advantage with clopidogrel. Available OTC in some markets.
PK: THE CLEARANCE IS RIGHT TO 0.3% AND NO ABSORPTION RATE CAN REPRODUCE THE PEAK. Against a verbatim "the AUC(0-infinity) were 301.12" at 10 mg this record predicts 300.1 — so the volume, bioavailability and half-life are COLLECTIVELY CORRECT and must not be moved on a failed verbatim check. But the Cmax-over-AUC identity is decisive in the other direction: the observed ratio is 0.656 per hour while the model ceiling at the published peak times is 52, 37 and 26 ng/mL against an observed 197. NO ka EXISTS THAT PRODUCES IT. Solving the identity gives an effective absorption window of five minutes once the enteric coat dissolves, which is exactly what an enteric-coated delayed-release tablet does — so the missing parameter is a LAG, not a rate, and the solver supports one. THE EMPTY EFFECT COMPARTMENT IS CORRECT AND THE ARGUMENT IS THE STRONGEST FORM YET FOUND: acid suppression builds over three to five days of once-daily dosing while the plasma profile is IDENTICAL on day one and day five, and A LINEAR FILTER HAS UNITY STEADY-STATE GAIN — its output tracks exposure per interval, which does not change — SO NO keo OF ANY MAGNITUDE PRODUCES DAY-OVER-DAY ACCUMULATION FROM A NON-ACCUMULATING CURVE. Recovery is set by proton-pump resynthesis, independent of concentration. The stored bioavailability is the label figure and correct; the cited paper is a RELATIVE study of granules in soft food.
Pharmacokinetics
- Oral — t½ 1 h · F 52% · Vd 25 L
Sources: PMID:22748970, PMID:21970660